NWBO vs. DNA

In the year-to-date period, NWBO achieves a -62.86% return, which is significantly higher than DNA's -85.09% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Northwest Biotherapeutics, Inc. (NWBO) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NWBO Sharpe Ratio is -0.99, which is comparable to the DNA Sharpe Ratio of -0.83. The chart below compares the historical Sharpe Ratios of NWBO and DNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NWBO nor DNA has paid dividends to shareholders.

The maximum NWBO drawdown since its inception was -99.99%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for NWBO and DNA. For additional features, visit the drawdowns tool.

The current volatility for Northwest Biotherapeutics, Inc. (NWBO) is 22.12%, while Ginkgo Bioworks Holdings, Inc. (DNA) has a volatility of 35.69%. This indicates that NWBO experiences smaller price fluctuations and is considered to be less risky than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Northwest Biotherapeutics, Inc. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.